EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

First‐line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non‐squamous non‐small cell lung cancer: Updated survival analysis of the ONO ‐4538‐52/ TASUKI ‐52 randomized controlled trial

Hye Ryun Kim, Shunichi Sugawara, Jong-Seok Lee, Jin-Hyoung Kang, Naoki Inui, Toyoaki Hida, Ki Hyeong Lee, Tatsuya Yoshida, Hiroshi Tanaka, Cheng-Ta Yang, Makoto Nishio, Yuichiro Ohe und 6 weitere

Cancer Medicine · 2023

DOI: 10.1002/cam4.6348 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancer Medicine, 2023. Verfasst von Hye Ryun Kim und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ono Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

ONO‐4538‐52/TASUKI‐52 was performed in Japan, Korea, and Taiwan to determine the oncological effectiveness and safety of combining nivolumab or placebo with bevacizumab plus platinum chemotherapy for the initial (first‐line) treatment of patients with advanced non‐squamous non‐small cell lung cancer (nsNSCLC). At the interim analysis (minimum follow‐up, 7.4 months), the independent radiology review committee‐assessed progression‐free survival was significantly longer in the nivolumab arm, but overall survival (OS) data were immature.

Methods

Here, we present the updated OS data. Patients with treatment‐naïve stage IIIB/IV or recurrent nsNSCLC without driver mutations in ALK , EGFR , or ROS1 , were randomized 1:1 to receive either nivolumab or placebo. Patients in both arms received paclitaxel, carboplatin, and bevacizumab, administered 3‐weekly for a maximum of 6 cycles. Nivolumab/placebo and bevacizumab were subsequently continued until disease progression or unacceptable toxicity.

Results

Overall, 550 patients were randomized. At the time of the analysis (minimum follow‐up: 19.4 months), the median OS was longer in the nivolumab arm than in the placebo arm (30.8 vs. 24.7 months; hazard ratio 0.74, 95% confidence interval 0.58–0.94). The 12‐month OS rates were 81.3% vs. 76.3% in the nivolumab vs. placebo arms, respectively. The respective 18‐month OS rates were 69.0% vs. 61.9%.

Conclusion

Nivolumab plus platinum chemotherapy and bevacizumab demonstrated longer OS vs. the placebo combination. We believe this regimen is viable as a standard, first‐line treatment for patients with advanced nsNSCLC without driver mutations in ALK , EGFR , or ROS1 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansNivolumabBevacizumabPaclitaxelCarboplatinPlatinumProtein-Tyrosine KinasesProto-Oncogene ProteinsNeoplasm Recurrence, LocalSurvival AnalysisErbB ReceptorsReceptor Protein-Tyrosine Kinases

Stichwörter der Autor:innen

bevacizumabchemotherapynivolumabnon-squamous non-small cell lung cancersurvival

Substanzen

NivolumabBevacizumabPaclitaxelCarboplatinPlatinumProtein-Tyrosine KinasesProto-Oncogene ProteinsErbB ReceptorsReceptor Protein-Tyrosine Kinases

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
  • Department of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi, Japan.
  • Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul, National University Bundang Hospital, Gyeonggi-do, South Korea.
  • Department of Medical Oncology, The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, South Korea.
  • Department of Pulmonary Medicine, Hamamatsu University Hospital, Shizuoka, Japan.
  • Department of Thoracic Oncology, Aichi Cancer Center, Aichi, Japan.

ORCID-Profile: Kazuhiko Nakagawa

Förderung

  • Ono Pharmaceutical

Zitieren

APA

Kim, H. R., Sugawara, S., Lee, J. S., Kang, J. H., Inui, N., Hida, T., Lee, K. H., Yoshida, T., Tanaka, H., Yang, C. T., Nishio, M., Ohe, Y., Tamura, T., Yamamoto, N., Yu, C. J., Akamatsu, H., Takahashi, S., & Nakagawa, K. (2023). First‐line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non‐squamous non‐small cell lung cancer: Updated survival analysis of the ONO ‐4538‐52/ TASUKI ‐52 randomized controlled trial. Cancer Medicine. https://doi.org/10.1002/cam4.6348

Vancouver

Kim HR, Sugawara S, Lee JS, Kang JH, Inui N, Hida T, et al. First‐line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non‐squamous non‐small cell lung cancer: Updated survival analysis of the ONO ‐4538‐52/ TASUKI ‐52 randomized controlled trial. Cancer Medicine. 2023. doi:10.1002/cam4.6348

BibTeX
@article{Kim2023,
  author = {Kim, Hye Ryun and Sugawara, Shunichi and Lee, Jong-Seok and Kang, Jin-Hyoung and Inui, Naoki and Hida, Toyoaki and Lee, Ki Hyeong and Yoshida, Tatsuya and Tanaka, Hiroshi and Yang, Cheng-Ta and Nishio, Makoto and Ohe, Yuichiro and Tamura, Tomohide and Yamamoto, Nobuyuki and Yu, Chong-Jen and Akamatsu, Hiroaki and Takahashi, Shigeru and Nakagawa, Kazuhiko},
  title = {First‐line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non‐squamous non‐small cell lung cancer: Updated survival analysis of the ONO ‐4538‐52/ TASUKI ‐52 randomized controlled trial},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6348}
}
Kostenlos starten →